Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1971 1
1972 1
1973 1
1975 21
1976 21
1977 20
1978 20
1979 21
1980 33
1981 36
1982 32
1983 34
1984 48
1985 44
1986 58
1987 69
1988 76
1989 75
1990 89
1991 85
1992 113
1993 104
1994 94
1995 121
1996 124
1997 142
1998 171
1999 173
2000 185
2001 233
2002 218
2003 241
2004 263
2005 306
2006 338
2007 354
2008 337
2009 392
2010 441
2011 499
2012 549
2013 529
2014 553
2015 550
2016 415
2017 287
2018 477
2019 477
2020 508
2021 592
2022 543
2023 428
2024 101

Text availability

Article attribute

Article type

Publication date

Search Results

10,462 results

Results by year

Filters applied: . Clear all
Page 1
Clinical implications of T cell exhaustion for cancer immunotherapy.
Chow A, Perica K, Klebanoff CA, Wolchok JD. Chow A, et al. Nat Rev Clin Oncol. 2022 Dec;19(12):775-790. doi: 10.1038/s41571-022-00689-z. Epub 2022 Oct 10. Nat Rev Clin Oncol. 2022. PMID: 36216928 Free PMC article. Review.
However, cancer is associated with T cell exhaustion, a hypofunctional state characterized by progressive loss of T cell effector functions and self-renewal capacity. The 'un-exhausting' of T cells in the tumour microenvironment is commonly regarded as a key …
However, cancer is associated with T cell exhaustion, a hypofunctional state characterized by progressive loss of T cell effec …
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schröder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, Li Y, Hamadene L, Flamar AL, Choi H, Cortez CA, Liu C, Holland A, Schad S, Schulze I, Betof Warner A, Hollmann TJ, Arora A, Panageas KS, Rizzuto GA, Duhen R, Weinberg AD, Spencer CN, Ng D, He XY, Albrengues J, Redmond D, Egeblad M, Wolchok JD, Merghoub T. Hirschhorn D, et al. Among authors: chow a. Cell. 2023 Mar 30;186(7):1432-1447.e17. doi: 10.1016/j.cell.2023.03.007. Cell. 2023. PMID: 37001503 Free PMC article.
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant clones. ...As expected, early on-target recognition of melanoma antigens by tumor-specific CD4(+) T cells was required. Surprisingly, …
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant …
Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Oh DY, et al. Among authors: chow e. Cell. 2020 Jun 25;181(7):1612-1625.e13. doi: 10.1016/j.cell.2020.05.017. Epub 2020 Jun 3. Cell. 2020. PMID: 32497499 Free PMC article.
Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection are unknown. T cells from human bladder tumors and non-malignant tissue were assessed with single-cell RNA and paired T cell rec …
Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection ar …
A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy.
Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y, Wang G, Dai X, Du Y, Kim HR, Cao H, Errami Y, Clark P, Bersenev A, Montgomery RR, Chen S. Ye L, et al. Among authors: chow rd. Cell Metab. 2022 Apr 5;34(4):595-614.e14. doi: 10.1016/j.cmet.2022.02.009. Epub 2022 Mar 10. Cell Metab. 2022. PMID: 35276062 Free PMC article.
Finding the right molecular targets to engineer T cells toward a desired function has broad implications for the armamentarium of T cell-centered therapies. Here, we developed a dead-guide RNA (dgRNA)-based CRISPR activation screen in primary CD8(+) T cells a …
Finding the right molecular targets to engineer T cells toward a desired function has broad implications for the armamentarium of …
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
Pai JA, Hellmann MD, Sauter JL, Mattar M, Rizvi H, Woo HJ, Shah N, Nguyen EM, Uddin FZ, Quintanal-Villalonga A, Chan JM, Manoj P, Allaj V, Baine MK, Bhanot UK, Jain M, Linkov I, Meng F, Brown D, Chaft JE, Plodkowski AJ, Gigoux M, Won HH, Sen T, Wells DK, Donoghue MTA, de Stanchina E, Wolchok JD, Loomis B, Merghoub T, Rudin CM, Chow A, Satpathy AT. Pai JA, et al. Among authors: chow a. Cancer Cell. 2023 Apr 10;41(4):776-790.e7. doi: 10.1016/j.ccell.2023.03.009. Epub 2023 Mar 30. Cancer Cell. 2023. PMID: 37001526 Free PMC article.
Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for enhanced resolution of clonal T cell dynamics in cancer. ...Regions with viable cancer cells are enriched for exhausted CD8(+) T cells, regulatory CD4(+) T cells (Tre …
Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for enhanced resolution of clonal T cell dyn …
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.
Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, Lam SZ, Zhou JJ, Lannin DR, Herbst RS, Chen S. Dong MB, et al. Among authors: chow rd. Cell. 2019 Aug 22;178(5):1189-1204.e23. doi: 10.1016/j.cell.2019.07.044. Cell. 2019. PMID: 31442407 Free PMC article.
CD8 T cells play essential roles in anti-tumor immune responses. Here, we performed genome-scale CRISPR screens in CD8 T cells directly under cancer immunotherapy settings and identified regulators of tumor infiltration and degranulation. ...Dhx37 knockout enhanced …
CD8 T cells play essential roles in anti-tumor immune responses. Here, we performed genome-scale CRISPR screens in CD8 T cells …
The ectonucleotidase CD39 identifies tumor-reactive CD8(+) T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM. Chow A, et al. Immunity. 2023 Jan 10;56(1):93-106.e6. doi: 10.1016/j.immuni.2022.12.001. Epub 2022 Dec 26. Immunity. 2023. PMID: 36574773 Free PMC article.
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8(+) T cells. ...Immune checkpoint blockade (ICB), but not cytotoxic chemotherapy, increased intratumoral CD39(+) …
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate o …
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, Liau LM, Cloughesy T, Hugo W, Prins RM. Lee AH, et al. Among authors: chow f. Nat Commun. 2021 Nov 26;12(1):6938. doi: 10.1038/s41467-021-26940-2. Nat Commun. 2021. PMID: 34836966 Free PMC article.
We identify an early activated and clonally expanded CD8+ T cell cluster whose TCR overlaps with a CD8+ PBMC population. ...Interferon-mediated changes in the myeloid population are consistently observed following PD-1 blockade; these also mediate an increase in chemotacti …
We identify an early activated and clonally expanded CD8+ T cell cluster whose TCR overlaps with a CD8+ PBMC population. ...Interfero …
CTLA-4 tail fusion enhances CAR-T anti-tumor immunity.
Zhou X, Cao H, Fang SY, Chow RD, Tang K, Majety M, Bai M, Dong MB, Renauer PA, Shang X, Suzuki K, Levchenko A, Chen S. Zhou X, et al. Among authors: chow rd. bioRxiv [Preprint]. 2023 Mar 15:2023.03.14.532655. doi: 10.1101/2023.03.14.532655. bioRxiv. 2023. Update in: Nat Immunol. 2023 Sep;24(9):1499-1510. doi: 10.1038/s41590-023-01571-5. PMID: 36993364 Free PMC article. Updated. Preprint.
Here, utilizing the endocytic feature of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) cytoplasmic tail (CT), we reprogram CAR function and substantially enhance CAR-T efficacy in vivo . ...These findings illuminate a unique strategy for engineering thera …
Here, utilizing the endocytic feature of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) cytoplasmic tail (CT), we reprogram …
CTLA-4 tail fusion enhances CAR-T antitumor immunity.
Zhou X, Cao H, Fang SY, Chow RD, Tang K, Majety M, Bai M, Dong MB, Renauer PA, Shang X, Suzuki K, Levchenko A, Chen S. Zhou X, et al. Among authors: chow rd. Nat Immunol. 2023 Sep;24(9):1499-1510. doi: 10.1038/s41590-023-01571-5. Epub 2023 Jul 27. Nat Immunol. 2023. PMID: 37500885
Here utilizing the endocytic feature of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) cytoplasmic tail, we reprogram CAR function and substantially enhance CAR-T efficacy in vivo. ...These findings illuminate a unique strategy for engineering therapeutic …
Here utilizing the endocytic feature of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) cytoplasmic tail, we reprogram CAR f …
10,462 results
You have reached the last available page of results. Please see the User Guide for more information.